THURSDAY, May 9, 2019 (HealthDay News) — A generic version of the HIV preexposure prophylaxis (PrEP) drug Truvada will be available in the United States by September 2020, a year earlier than expected, according to Gilead Sciences.
“Gilead reached an agreement with Teva Pharmaceuticals in 2014 to allow the early launch of a generic version of Truvada into the market in 2020, a year earlier than required,” Douglas Brooks, Gilead executive director for community engagement, wrote in an email shared with NBC News by the advocacy group PrEP4All.
A month’s supply of generic Truvada is available in countries around the world for as little as $70, but the drug costs $1,600 to $2,000 in the United States.
Activists launched a campaign to convince Gilead to make the generic drug more widely available to combat the global HIV epidemic, NBC News reported.
Copyright © 2017 HealthDay. All rights reserved.